May 31st on Gelunhui | Maiwei Biotechnology (688062.SH) quickly rose more than 6% in the afternoon, now reporting 34.7 yuan, with a total market value of 13.87 billion yuan. GF Securities' research reports point out that the company's 9MW2821 has been selected for the 2024 ASCO oral report, focusing on its market potential in various solid tumors. 9MW2821 shows better treatment effects in more indications, and the company has realized the layout of the entire industry chain, making its pharma growth promising. The determination to maintain the company's reasonable value of 39.20 yuan/share and the 'buy' rating remain unchanged.
A股异动 | 迈威生物午后涨超7% 9MW2821亮相ASCO
A-share changes | Maiwei Biotech rose more than 7% in the afternoon, 9MW2821 debuted at ASCO
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.